Esenlote Eye Drop contains Loteprednol etabonate 0.5% w/v, a corticosteroid indicated for the treatment of inflammatory conditions of the eye. It is primarily used to manage ocular inflammation and pain associated with allergic conjunctivitis, postoperative inflammation following ocular surgery, and anterior uveitis. Loteprednol etabonate exhibits potent anti-inflammatory properties by inhibiting the release of inflammatory mediators and reducing leukocyte infiltration. The formulation is designed for topical ocular administration, ensuring targeted delivery with minimal systemic absorption. Esenlote Eye Drop should be used under medical supervision, with dosing tailored according to the severity of the condition and patient response. Common administration involves instilling one to two drops into the affected eye(s) two to four times daily. Prolonged use may increase the risk of elevated intraocular pressure, glaucoma, cataract formation, or secondary ocular infections; therefore, regular monitoring by an ophthalmologist is recommended. Patients should avoid contact lens use during treatment unless advised otherwise. Esenlote Eye Drop is contraindicated in viral, fungal, or mycobacterial ocular infections. Caution is advised in patients with a history of steroid-induced ocular hypertension. Proper storage and adherence to prescribed duration are essential to maximize therapeutic benefits and minimize adverse effects.